View:
Download DOC
Download PDF
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Suria Hamza
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10421 PACIFIC CENTER COURT, SUITE 200
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/25/2017 		3. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO INC [ ANAB ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President, CEO
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Preferred Stock (1) (1) Common Stock 2,197 0.00 D
Series C-1 Preferred Stock (1) (1) Common Stock 781 0.00 D
Series D Preferred Stock (1) (1) Common Stock 2,020 0.00 D
Employee Stock Option (right to buy) (2) 12/08/2018 Common Stock 22,428 2.59 D
Employee Stock Option (right to buy) (2) 02/09/2020 Common Stock 1,428 2.24 D
Employee Stock Option (right to buy) (2) 02/23/2021 Common Stock 6,208 1.61 D
Employee Stock Option (right to buy) (2) 12/08/2021 Common Stock 140,948 1.12 D
Employee Stock Option (right to buy) (2) 01/31/2022 Common Stock 73,291 1.12 D
Employee Stock Option (right to buy) (3) 01/31/2022 Common Stock 97,721 1.12 D
Employee Stock Option (right to buy) (4) 12/16/2022 Common Stock 19,425 0.91 D
Employee Stock Option (right to buy) (5) 09/15/2024 Common Stock 51,840 0.7 D
Employee Stock Option (right to buy) (6) 08/13/2025 Common Stock 265,928 6.93 D
Explanation of Responses:
1. Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.
2. The stock option is fully vested and immediately exercisable.
3. The stock option becomes 100% vested upon the Issuer's initial public offering, subject to the Reporting Person's employment on such date.
4. The stock option vested and became exercisable as to 25% of the shares subject to the option on December 17, 2013, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
5. The stock option vested and became exercisable as to 25% of the shares subject to the option on September 16, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
6. The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
Remarks:
/s/ Hamza Suria 01/25/2017
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

	KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints Dominic Piscitelli, Ryan McRobert, Nanette Agustines and Winston
Macaraeg, and each of them, as his or her true and lawful attorney-in-fact to:

	(1)	execute for and on behalf of the undersigned, in the undersigned's capacity
as a representative of AnaptysBio, Inc. (the "Company"), any and all Form ID, or
Form 3, 4 or 5 reports and any amendments thereto required to be filed by the
undersigned in accordance with Section 16(a) of the Securities Exchange Act of
1934 (the "Exchange Act") and the rules thereunder with respect to transactions
in the Company's securities;
	(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID, or Form
3, 4 or 5 report and any amendments thereto and timely file such report with the
U.S. Securities and Exchange Commission and any stock exchange or similar
authority; and
	(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney in-fact may approve in his or
her discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary, and proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or his or her
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this Power of Attorney and the rights and powers herein granted.  The
undersigned acknowledges that no such attorney in-fact, in serving in such
capacity at the request of the undersigned, is hereby assuming, nor is the
Company hereby assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Form 3, 4 or 5 reports with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 20th day of January, 2017.


/s/ Hamza Suria
Hamza Suria